问题 › 我们不知道谁是最佳客户 › 医疗服务提供商
最佳并不意味着最大的归属患者数或最多的归属生命。它指在基于价值的合同下，能用已知每集成本管理的归属生命，服务于每个提供商贡献利润率范围内，并在合同周期内保留。 对医疗服务提供商而言，难点在于结构：已在没有每集成本数据的情况下接受了38,000个生命的 downside risk。任何可信答案都必须同时掌握每集成本与支付方组合，而这正是大多数内部分析停滞之处，因为两者分属不同系统。
最佳并不意味着最大的归属患者数或最多的归属生命。它指在基于价值的合同下，能用已知每集成本管理的归属生命，服务于每个提供商贡献利润率范围内，并在合同周期内保留。 对医疗服务提供商而言，难点在于结构：已在没有每集成本数据的情况下接受了38,000个生命的 downside risk。任何可信答案都必须同时掌握每集成本与支付方组合，而这正是大多数内部分析停滞之处，因为两者分属不同系统。
大多数提供商能说出按归属生命数排名的最大群体，但很少能说出最佳群体。最佳需要把三件事合在一起，而这三件事通常分在不同系统：支付方组合带来的贡献、每集管理成本，以及价值-based合同下群体规模的稳定性。
结果往往出乎意料。按归属生命数最大的群体，一旦纳入每集成本后排名常常居中；最佳群体往往是没人刻意瞄准的，通过特定支付方组合发现，从未围绕贡献系统化。
这决定下游所有决策：追求哪些基于价值的合同、如何分配群体规模、如何设定每集定价、哪些临床路径需要标准化。搞错就等于让整个提供商群体为错误的归属生命优化。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 最佳归属生命意味着CFO与医务主任对话中最大的群体规模
✓ 每集成本未按支付方组合或群体细分拆分
✓ 基于价值的合同目标画像来自内部假设，而非现有38,000个归属生命
通常会让情况更糟的做法。 从基于价值合同下最大的群体定义目标归属生命，这选出的往往是谈判权最强的群体，而非每集成本经济性最好的群体。
It is for you if you run or finance a healthcare provider and best customer means largest by revenue in internal conversation. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Turn $6.8 M downside-risk liability into a $22–35 M licensing platform within 36 months.
The leak it closes. Eliminates $6.8 M downside exposure by enabling proactive utilization management.
The assumption it rests on. Cost-measurement platform achieves <5 % variance versus manual abstraction within 12 months — the engine put the probability at 0.75.
| Investment required | $2.1–3.5 M over 36 months |
| Expected return | 6.3–16.7× cash-on-cash within 36 months based on $196 M current revenue base. |
| Revenue, year 1 | $0 licensing revenue; $1.8 M internal cost avoidance |
| Revenue, year 2 | $4.2 M licensing ARR (40 physicians × $120K + 5 external practices × $400K) |
| Revenue, year 3 | $13.5 M licensing ARR (90 physicians × $120K + 18 external practices × $400K) plus $4–8 M shared-savings upside |
| Exit criteria | Terminate platform investment if variance exceeds 8 % by Month 18 OR if fewer than 40 physicians sign licensing agreements by Month 24; redeploy remaining capital to ASC surgeon-retention track. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Customer Value Architecture, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
在细分层面把贡献、获取成本和留存结合起来。单独用其中任何一项，得到的排名都会自信地出错。
这通常是好事——它给出明确的瞄准指令。真正的问题是这个群体是否大到能支撑增长计划，这个问题有答案。
先重新定价；部分会变得盈利，其余的离开时决策已替你做好。直接放弃更快，却会损失哪些可以重新定价的信息。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית